| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 12/02/2004 | WO2004078947A3 Use of thyroid-stimulating hormone to induce lipolysis |
| 12/02/2004 | WO2004076413A3 Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| 12/02/2004 | WO2004072031A3 Phenylacetamides and their use as glucokinase modulators |
| 12/02/2004 | WO2004042064A3 Disorders of lipid metabolism |
| 12/02/2004 | WO2003095667A3 Autoimmune conditions and nadph oxidase defects |
| 12/02/2004 | WO2003039452A3 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 12/02/2004 | US20040242928 Reverse hydroxamic acid derivatives |
| 12/02/2004 | US20040242898 Antidiabetic agents; metabolism diosrders; hypotensive agents; cardiovascular disorders; reacting 2,2,3,3-tereafluorobutane with primary amine; cyclization |
| 12/02/2004 | US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis |
| 12/02/2004 | US20040242853 Glp-1 exendin-4 peptide analogs and uses thereof |
| 12/02/2004 | US20040242692 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis |
| 12/02/2004 | US20040242678 Apolipo protein e secretion promoters |
| 12/02/2004 | US20040242675 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 12/02/2004 | US20040242672 Pyrrolidine derivatives |
| 12/02/2004 | US20040242668 Capable of increasing lipolysis and energy expenditure in cells and therefore is useful for treating Type 2 diabetes and/or obesity |
| 12/02/2004 | US20040242657 Reaction of a phenoxypropionic acid compound with a trifluoromethylphenylthiazole compound; for manufacture of a medicament for treatment of a human peroxisome proliferator activated receptor alpha mediated disease or condition such as hypercholesteremia, cardiovascular disease |
| 12/02/2004 | US20040242647 Use of organic compounds |
| 12/02/2004 | US20040242637 drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals |
| 12/02/2004 | US20040242636 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity |
| 12/02/2004 | US20040242633 Compound used to lower cholesterol, reduce weight for dietetics, antidepressants and antidiabetic agents |
| 12/02/2004 | US20040242613 Pyrimidine derivatives useful as inhibitors of PKC-theta |
| 12/02/2004 | US20040242589 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| 12/02/2004 | US20040242575 for use with various disorders including sleep disorders; depression; cardiovascular disorders; pain; neurodegenerative disorders; psychiatric disorders etc. |
| 12/02/2004 | US20040242574 Anticancer agents; antiarthritic agents |
| 12/02/2004 | US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives |
| 12/02/2004 | US20040242544 Stabilized derivatives of ascorbic acid-3-phosphate |
| 12/02/2004 | US20040242516 Antisense modulation of apolipoprotein(a) expression |
| 12/02/2004 | US20040242515 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis |
| 12/02/2004 | US20040242508 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same |
| 12/02/2004 | US20040242506 Formed from paroxetine hydrochloride and ammonium glycyrrhyzinate by precipitation, spray, vacuum or freeze drying, or evaporation to glass; solid or oil; masks the bitter taste of paroxetine and has a distinctive licorice flavor; antidepressants; Parkinson's disease |
| 12/02/2004 | US20040242487 Identifying a subject in need of inhibiting appetite or weight gain and administering an effective amount of an antagonist of melanocyte concentrating hormone (MCH) to subject, wherein antagonist binds an MCH receptor |
| 12/02/2004 | US20040242480 Method for treating coumarin-induced hemorrhage |
| 12/02/2004 | US20040242479 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 12/02/2004 | US20040242474 High density lipoprotein-reactive peptides |
| 12/02/2004 | US20040242472 Use of artemin, a member of the gdnf ligand family |
| 12/02/2004 | US20040242462 Detecting that individual's Tob gene, transcript and/or protein and comparing with normal Tob gene, transcript and/or protein, differences present indicating that the probability of that individual suffering from amnesia |
| 12/02/2004 | US20040241803 25 human secreted proteins |
| 12/02/2004 | US20040241761 Using human estrogen receptor gene expression as diagnostic indicator of diabetes; antidiabetic agents |
| 12/02/2004 | US20040241249 Prepared by ketone extraction of krill; evaporating ketone in liquid product; 2nd extraction of the solids in the product with an alcohol or acetate solvent to form a soluble lipid fraction; separating liquids and solids in 2nd product and evaporating solvent from liquid fraction; recovering solids |
| 12/02/2004 | US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes |
| 12/02/2004 | US20040238781 Using genistein; preadministering before exposure to radiation; prevent tissue damage |
| 12/02/2004 | DE10308353A1 Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Diarylcycloalkylderivate, processes for their preparation and their use as medicaments |
| 12/02/2004 | CA2526637A1 Carboxylic acid compound and medecine comprising the same |
| 12/02/2004 | CA2526374A1 2-aminoquinoline derivatives |
| 12/02/2004 | CA2526349A1 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 12/02/2004 | CA2526027A1 Process for making spirolactone compounds |
| 12/02/2004 | CA2525945A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| 12/02/2004 | CA2525501A1 Tetrahydroisoquinoline derivatives as ppar-.alpha. activators |
| 12/02/2004 | CA2524531A1 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 12/01/2004 | EP1481989A1 A-33 related antigens and their pharmacological uses |
| 12/01/2004 | EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| 12/01/2004 | EP1481962A1 New cholesterolemia-lowering carboxyalkylether compound |
| 12/01/2004 | EP1481684A1 Remedies for liver diseases, hyperlipemia and diabetes |
| 12/01/2004 | EP1481675A1 Body temperature elevating agents |
| 12/01/2004 | EP1481671A1 Compositions and foods for improving lipid metabolism |
| 12/01/2004 | EP1481670A1 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 12/01/2004 | EP1481093A2 MODULATION OF TYPE II&bgr; PHOSPHOINOSITIDE PHOSPHATE KINASE |
| 12/01/2004 | EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells |
| 12/01/2004 | EP1481065A2 Method for detection of leptin receptor ligands |
| 12/01/2004 | EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 12/01/2004 | EP1480983A1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives |
| 12/01/2004 | EP1480981A1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives |
| 12/01/2004 | EP1480976A1 Thiazole derivatives as npy receptor antagonists |
| 12/01/2004 | EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| 12/01/2004 | EP1480972A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
| 12/01/2004 | EP1480964A1 Inhibiteurs de l'angiogenese |
| 12/01/2004 | EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 12/01/2004 | EP1480961A1 Glutaminyl based dpiv inhibitors |
| 12/01/2004 | EP1480960A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments |
| 12/01/2004 | EP1480959A1 Piperazine derivatives as anti-inflammatory agents |
| 12/01/2004 | EP1480957A1 Hppars activators |
| 12/01/2004 | EP1480951A1 Synthesis of indole thiazole compounds as ligands for the ah receptor |
| 12/01/2004 | EP1480950A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| 12/01/2004 | EP1480691A2 Agglomerated particles for aerosol drug delivery |
| 12/01/2004 | EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 12/01/2004 | EP1480678A2 Treatment of ophthalmic disorders using urea and urea derivatives |
| 12/01/2004 | EP1480670A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis |
| 12/01/2004 | EP1480668A1 Compositions and methods for promoting lipid mobilization, glycogen mobilization,or both, in humans |
| 12/01/2004 | EP1480663A1 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
| 12/01/2004 | EP1480642A1 Peroxisome proliferator activated receptor modulators |
| 12/01/2004 | EP1480641A1 Substituted thiazoles and oxazoles that modulate ppar activity |
| 12/01/2004 | EP1480640A1 Peroxisome proliferator activated receptor modulators |
| 12/01/2004 | EP1480623A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release |
| 12/01/2004 | EP1480621A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 12/01/2004 | EP1480613A1 Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer |
| 12/01/2004 | EP1480598A2 Manipulation of cytokine levels using cd83 gene products |
| 12/01/2004 | EP1318996B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 12/01/2004 | EP1280522B1 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use |
| 12/01/2004 | EP1263761B1 Compounds for pdt |
| 12/01/2004 | EP1214093B1 Method for producing a tablet made of isomaltulose, isomalt or isomalt variants and corresponding products |
| 12/01/2004 | EP1185539B1 Organosilyl compounds having nuclear hormone receptor modulating activity |
| 12/01/2004 | EP1175408B1 Pyrimidinone compounds |
| 12/01/2004 | EP1121449A4 Delivery system for porcine somatotropin |
| 12/01/2004 | EP0886637B1 Inhibitors of microsomal triglyceride transfer protein and method |
| 12/01/2004 | CN1551919A 治疗性结合分子 Therapeutic binding molecules |
| 12/01/2004 | CN1551914A FAD4, FAD5, FAD5-2 and FAD6, novel fatty acid desaturase family members and uses thereof |
| 12/01/2004 | CN1551871A Process for preparinga thiazole PPAR-ligand and polymorphs thereof |
| 12/01/2004 | CN1551869A Novel compound |
| 12/01/2004 | CN1551780A Oxynthomodulin for preventing or treating excess weight |
| 12/01/2004 | CN1551776A Method of treatment of type I diabetes |